15 Comments
User's avatar
Anthony Yeung, MD's avatar

Great review on the state of autoimmune psychosis! I am greatly looking forward to seeing the results from SINAPPS. I've long thought about whether psychiatrists should develop the competency to do LPs, which would in theory address some of the neurologist bottleneck. This however, would be a huge scope of practice change and very unlikely to happen in Canada where I practice. Is there any thought about psychiatrists taking on LPs in the UK?

Thomas Reilly's avatar

Thank you! There always conversations about us doing lumbar punctures but I’ve not seen it in practice. I was quite adept after doing a neurology job but quickly lost the skill after starting psychiatry.

I think we would also need senior (support, eg from anaesthetics or neurology) for tricky cases and access to neuroimaging - it would be a sea change in how we work

Cymande Baxter-Rogers's avatar

I've wondered about NMDA receptor capacity, structure and function in patients who have no response to IV ketamine in clinic. Perhaps that experience could be a kind of filter for finding future trial participants.

Michael Halassa's avatar

This is great! Just a historical note on this: Dalmau did not do the original work in Barcelona. It was in Philadelphia (at Penn). I know because he was right across the hall from me when I was a grad student. In fact, I missed his presentation on the original cases in our lab meeting (my supervisor invited him as a guest speaker), and one of my colleagues told me about it later on as an interesting preliminary ‘clinical thing’ that was well outside of our domain. Interesting how life worked afterwards and I certainly regret missing that lab meeting (don’t even remember why I missed it!)

Thomas Reilly's avatar

Sorry, you’re right! Thanks for the spot, I’ll correct this 🙂

It seems academia is a small world

Michael Halassa's avatar

Oh no, I didn’t mean this as a correction like that. I think most people associate Josep with Barcelona. I just wanted to go down memory lane and you allowed me to so thank you!

Sharon Rosen Lopez's avatar

Thank you for doing this research! I wonder if you’ve found elevated sedimentation rate in your patients with antibodies to the NMDA receptors. I ask because autoimmune disease and psychotic disorders are prevalent in my family, and the lab work of a family member who has a psychotic disorder has come back showing elevated sedimentation rate (though antinuclear antibody levels are WNR).

Thomas Reilly's avatar

That’s kind of you to say, but I’m not the one who’s done any of the hard work here!

Are you talking about erythrocyte sedimentation rate (ESR)? My understanding is that this is a fairly nonspecific marker of inflammation, like C-reactive protein. I imagine it is mildly elevated on average in patients with psychosis but difficult to interpret the clinical significance.

There are definitely associations between autoimmune disease and psychosis - https://pubmed.ncbi.nlm.nih.gov/30122288/ - but again difficult to know if this is relevant for any individual patient

Sharon Rosen Lopez's avatar

Thanks very much for your response. Yes, I was referring to ESR, and yes, there’s quite a maze to figuring things out. I look forward to seeing your research results.

Dr Erik Smedler's avatar

I general I think we as psychiatrists should manage all patients with psychosis, sometimes with help from other specialities. That way we develop and not loose somatic skills.

Sonya Lazarevic MD, MS's avatar

Great article! with autoimmune conditions on the rise, I'm not surprised to see this increase, or a higher incidence amongst women. In the past few years I've increasingly paid attention to the gut-immune-brain axis and screen my patients for inflammatory markers (amongst other heath markers) to understand their general health. Inflammation affects the integrity of the BBB and impacts brain health (such as depression). Thanks for raising awareness on this topic.

SM's avatar

Tom’s piece on inflammatory reductionism foreshadowed this excellent piece. We have quite a few cases of “antibody negative” patients with catatonia who have received treatment with immunosuppressants; especially in those without MRI or EEG findings or pleocytosis this is particularly troubling for me, although I have seen some post hoc benefit. I am been in the habit of sending neurofilament light chain in many patients to assess for degree of neuronal damage.

Dr. Nicole Mirkin's avatar

he distinction between autoimmune encephalitis with psychiatric presentation and a putative “autoimmune psychosis” without neurological evolution is often collapsed in public discourse, and your review shows why that leap isn’t currently justified. The low base rates, lack of phenotype specificity, presence of antibodies in healthy controls, and uncertainty about CNS pathogenicity all argue for caution. SINAPPS feels exactly like the right kind of work here — slow, difficult, and methodologically disciplined — because the stakes are high in both directions: missing a reversible cause versus medicalizing noise. The outcome, positive or negative, will meaningfully sharpen clinical reasoning rather than expand indiscriminate testing.